Effects of an angiotensin-converting enzyme inhibitor and a β-blocker on cerebral arterioles in rats

被引:51
|
作者
Chillon, JM
Baumbach, GL
机构
[1] Univ Iowa, Coll Med, Dept Pathol, Med Labs 100, Iowa City, IA 52242 USA
[2] Univ Iowa, Ctr Cardiovasc, Iowa City, IA 52242 USA
关键词
hypertension; chronic; vascular remodeling; angiotensin; hypertrophy; vascular;
D O I
10.1161/01.HYP.33.3.856
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
We examined the effects of an angiotensin-converting enzyme inhibitor, perindopril, and a beta-blocker, propranolol, on cerebral arterioles in stroke-prone spontaneously hypertensive rats (SHRSP). The structure and mechanics of cerebral arterioles were examined in untreated Wistar-Kyoto rats (WKY) and SHRSP that were untreated or treated for 3 months with a high (2 mg/kg per day) or a low (0.3 mg/kg per day) dose of perindopril or propranolol (250 mg/kg per day) alone or in combination with the low dose of perindopril. We measured pressure, external diameter, and cross-sectional area of the vessel wall (CSA) in maximally dilated (with EDTA) cerebral arterioles. Treatment of SHRSP with the high dose of perindopril or the combination of propranolol and the low dose of perindopril normalized cerebral arteriolar mean pressure (50+/-1 [mean+/-SEM] and 43+/-2 mm Hg vs 50+/-1 mm Hg in WKY and 94+/-3 mm Hg in untreated SHRSP; P<0.05), pulse pressure (15+/-1 and 16+/-1 mm Hg vs 13+/-1 mm Hg in WKY and 35+/-1 mm Hg in untreated SHRSP; P<0.05), and CSA (1103+/-53 and 1099+/-51 mu m(2), respectively, vs 1057+/-49 mu m(2) in WKY and 1281+/-67 mu m(2) in untreated SHRSP; P<0.05). In contrast, treatment of SHRSP with the law dose of perindopril or propranolol alone did not normalize arteriolar pulse pressure (24+/-1 and 21+/-1 mm Hg) and failed to prevent increases in CSA (1282+/-77 and 1267+/-93 mu m(2)). Treatment with either dose of perindopril or the combination of propranolol and perindopril significantly increased external diameter in cerebral arterioles of SHRSP (99+/-3, 103+/-2, and 98+/-3 mu m vs 87+/-2 mu m in untreated SHRSP; P<0.05), whereas propranolol alone did not (91+/-3 mu m; P>0.05). These findings suggest that effects of angiotensin-converting enzyme inhibitors on cerebral arteriolar hypertrophy in SHRSP map depend primarily on their effects on arterial pressure, particularly pulse pressure, whereas their effects on cerebral arteriolar remodeling (defined as a reduction in external diameter) may be pressure independent.
引用
收藏
页码:856 / 861
页数:6
相关论文
共 50 条
  • [31] Natural History of Cardiomyopathy in Duchenne Muscular Dystrophy and the Effects of Angiotensin-Converting Enzyme Inhibitor with or without β-Blocker
    Thrush, Philip
    Viollet, Laurence
    Flanigan, Kevin
    Mendell, Jerry
    Allen, Hugh
    NEUROLOGY, 2012, 78
  • [32] Beneficial Effects of Combination Therapy with Angiotensin II Receptor Blocker and Angiotensin-Converting Enzyme Inhibitor on Vascular Endothelial Function
    Satoshi Morimoto
    Kei Maki
    Yasuko Aota
    Takao Sakuma
    Toshiji Iwasaka
    Hypertension Research, 2008, 31 : 1603 - 1610
  • [33] Beneficial Effects of Combination Therapy with Angiotensin II Receptor Blocker and Angiotensin-Converting Enzyme Inhibitor on Vascular Endothelial Function
    Morimoto, Satoshi
    Maki, Kei
    Aota, Yasuko
    Sakuma, Takao
    Iwasaka, Toshiji
    HYPERTENSION RESEARCH, 2008, 31 (08) : 1603 - 1610
  • [34] Vascular protective effects of combined therapy of angiotensin receptor blocker and angiotensin-converting enzyme inhibitor in essential hypertension.
    Morimoto, Satoshi
    Tokoro, Toshiko
    Kikuchi, Sanae
    Yamahara, Hideki
    Imada, Takanobu
    Kohno, Keiko
    Masaki, Hiroya
    Takahashi, Nobuyuki
    Nishikawa, Mitsushige
    Iwasaka, Toshiji
    JOURNAL OF HYPERTENSION, 2006, 24 : 190 - 190
  • [35] TOXICITY STUDY OF THE ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR RENTIAPRIL IN RATS
    TAKASE, K
    IKUSE, T
    AONO, H
    OKAHARA, A
    ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 1995, 45-1 (01): : 15 - 18
  • [36] The regression of vascular changes in hypertension - calcium channel blocker or angiotensin-converting enzyme inhibitor?
    Czarnecka, Danuta
    Styczkiewicz, Katarzyna
    ARTERIAL HYPERTENSION, 2005, 9 (06): : 489 - 498
  • [37] Efficacy of combination therapy with angiotensin-converting enzyme inhibitor and calcium channel blocker in hypertension
    Redon, Josep
    Trenkwalder, Peter R. A.
    Barrios, Vivencio
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (02) : 155 - 164
  • [38] Prevention of osteoporosis by angiotensin-converting enzyme inhibitor in spontaneous hypertensive rats
    Hideo Shimizu
    Hironori Nakagami
    Mariana Kiomy Osako
    Futoshi Nakagami
    Yasuo Kunugiza
    Tetsuya Tomita
    Hideki Yoshikawa
    Hiromi Rakugi
    Toshio Ogihara
    Ryuichi Morishita
    Hypertension Research, 2009, 32 : 786 - 790
  • [39] EFFECTS OF CHRONIC ADMINISTRATION OF AN ANGIOTENSIN-CONVERTING ENZYME-INHIBITOR ON ANGIOTENSIN-CONVERTING ENZYME-ACTIVITY IN THE PARS RECTA OF RABBITS
    PRADDAUDE, F
    TRANVAN, T
    MARCHETTI, J
    GIROLAMI, JP
    ADER, JL
    CLINICAL SCIENCE, 1990, 79 (01) : 29 - 35
  • [40] Mechanisms of angiotensin-converting enzyme inhibitor induced thrombolysis in Wistar rats
    Gryglewski, RJ
    Swies, J
    Uracz, W
    Chlopicki, S
    Marcinkiewicz, E
    THROMBOSIS RESEARCH, 2003, 110 (5-6) : 323 - 329